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In the present issue of the journal, Makoto Noda 
and colleagues present a screening assay for anti-cancer 
drugs based on tumor reversion, identifying a series of 
hitherto unsuspected compounds that are of potential 
therapeutic  interest.  More  specifically,  the  assay  is 
based upon triggering the promoter of Reck, which 
functions as an inhibitor of metalloproteinases. Among 
the pharmaceutical agents that were able to activate the 
Reck promoter, 1/3 were known anti-cancer drugs which 
act through different cytopathic mechanisms. The second 
group comprises drugs that inhibit growth of bacteria, 
plasmodium falciparum, fungi and worms. The third 
category consists of “drugs related to the function of the 
central nervous system”. 
Now, here comes the interesting and original idea 
of the paper. Activation of Reck induces “flat revertants” 
and Noda used this system already to clone the K-rev 
gene [1, 2]. Flat revertants have a history of their own 
that started when investigators in the early 1960s used 
the NIH3T3 cells to assay the transforming potential 
of oncoviruses and oncogenes. A couple of years later 
in  1968,  when  Robert  Pollack  stepped  into  the  field, 
he made a remarkable observation. Some of the cells 
infected with SV40 or polyoma viruses no longer showed 
the typical oncogenic phenotype, but instead, acquired 
a  flat  morphology  [3].  These  cells  had  also  lost  their 
oncogenic  potential  and  were  therefore  named  “flat 
revertants”. This reversion of the malignant phenotype 
was in line with the experiments initiated by Askanazy in 
teratocarcinoma cells at the beginning of the 20th century 
and later expanded to different species and cell types 
[4]. The most spectacular tumor reversion experiments 
have been carried out in plants by Braun [4].  Various 
approaches, using different biological systems [5, 6 ,7] 
led to the identification of at least 300 genes that could 
be implicated in the tumor reversion process, including 
siah1, PS1, TSAP6, TCTP, Integrin receptors, and Nodal. 
Interestingly, Nodal is an embryonic morphogen recently 
found to be a key plasticity gene in aggressive tumor 
cells. Down-regulation of Nodal in this plastic phenotype 
results in reversion to a lineage specific cell type and 
tumor suppression [8]. 
Targeting tumor reversion genes in order to induce a 
suppression of the malignant phenotype has already led to 
the identification of a series of anti-histaminic, neuroleptic 
and anti-depressive drugs that inhibit intra-cellular levels 
of TCTP, a key gene in tumor reversion [9]. Other genes 
such as PS1, a predisposition gene to familial Alzheimer’s 
disease targeted by gamma-secretase inhibitors are tested 
in Kaposi sarcoma patients [4].
Tumor reversion as used here in Noda’s study [10] 
can be a fast-track for the identification of new anti-cancer 
drugs when we are still far away from understanding how 
reversion functions at the molecular level, and this is a 
major future challenge. 
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